News and Trends 23 Oct 2017
Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval
DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of a Phase III trial that was key to the approval of a treatment to reduce peanut allergy in children. After 12 months, 35% of children […]